Literature DB >> 33595893

Immunotherapy for pancreatic ductal adenocarcinoma.

Eileen Carpenter1, Sarah Nelson2, Filip Bednar2, Clifford Cho2, Hari Nathan2, Vaibhav Sahai3, Marina Pasca di Magliano2, Timothy L Frankel2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors. Here, we review the molecular components responsible for the immune-privileged state in PDAC and provide an overview of the immunotherapeutic strategies for PDAC including vaccine therapy, checkpoint blockade, myeloid-targeted therapy, and immune agonist therapy.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  immunotherapy; microenvironment; pancreatic cancer

Year:  2021        PMID： 33595893     DOI： 10.1002/jso.26312

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  7 in total

1.  A Potential Prognostic Marker PRDM1 in Pancreatic Adenocarcinoma.

Authors:  Bo Zhou; Jie Zhang; Hongda Zhu; Shugeng Wu
Journal:  J Oncol       Date:  2022-05-13       Impact factor: 4.501

Review 2.  Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients.

Authors:  Heidelinde Sammallahti; Arto Kokkola; Sama Rezasoltani; Reza Ghanbari; Hamid Asadzadeh Aghdaei; Sakari Knuutila; Pauli Puolakkainen; Virinder Kaur Sarhadi
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

3.  Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer.

Authors:  Tyler MacNeil; Ioannis A Vathiotis; Saba Shafi; Thazin Nwe Aung; Jon Zugazagoitia; Aaron M Gruver; Kyla Driscoll; David L Rimm
Journal:  Cancers (Basel)       Date:  2021-11-02       Impact factor: 6.639

4.  Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer.

Authors:  Sang-In Kim; Shyambabu Chaurasiya; Venkatesh Sivanandam; Seonah Kang; Anthony K Park; Jianming Lu; Annie Yang; Zhifang Zhang; Isabella A Bagdasarian; Yanghee Woo; Joshua T Morgan; Zhirong Yin; Yuman Fong; Susanne G Warner
Journal:  Mol Ther Oncolytics       Date:  2022-02-22       Impact factor: 7.200

5.  Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.

Authors:  Zhi-Gang Zhu; Lei Chen; Dong-Liu Miao; Yiqi Jin; Qiong Wu
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

6.  Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study.

Authors:  Yong-Gang He; Xiao-Bing Huang; Yu-Ming Li; Jing Li; Xue-Hui Peng; Wen Huang; Yi-Chen Tang; Lu Zheng
Journal:  World J Gastrointest Oncol       Date:  2022-09-15

7.  Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer.

Authors:  Thuy Phan; Vu H Nguyen; Ralf Buettner; Corey Morales; Lifeng Yang; Paul Wong; Weiman Tsai; Marcela d'Alincourt Salazar; Ziv Gil; Don J Diamond; Joshua D Rabinowitz; Steven Rosen; Laleh G Melstrom
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.